DOI: 10.4244/EIJV12I2A24

The current status of endovascular treatment for acute ischaemic stroke

Ismail Dogu Kilic1, MD; Omer Goktekin2*, MD

Stroke, a growing global healthcare burden, remains one of the leading culprits of disability and death in the Western world1. Ischaemic stroke accounts for the majority of all strokes, in which rapid restoration of blood flow to salvageable tissue at risk of infarction reduces the final area of infarct and provides better outcomes. For several years, fibrinolytic treatment with tissue plasminogen activator (tPA), within four and a half hours of the onset of symptoms, has been the primary reperfusion strategy in the treatment of acute ischaemic stroke. Nonetheless, limitations of tPA therapy, including the low rates of recanalisation in large vessel ischaemic strokes, have led to the development of endovascular approaches2,3. However, robust data to support endovascular therapy for stroke were previously lacking because of the futility in randomised trials. Despite these results, researchers have remained attentive to this approach and investigated endovascular stroke treatment in a number of trials, considering some prior limitations. Subsequently, data from MR CLEAN4, EXTEND-IA5, ESCAPE6, REVASCAT7, and SWIFT PRIME8 (and expected data from other forthcoming studies) have shown improved outcomes with endovascular therapy in patients with an acute ischaemic stroke due to an arterial occlusion of the anterior circulation. Careful selection of the candidates, identification of a major vessel occlusion prior to intervention with imaging studies and effective recanalisation (TICI 2b-3) that was achieved with stent retrievers in the majority of patients contributed to good clinical outcome in the trials. Moreover, these trials achieved highly efficient workflow metrics and a relatively short time to intervention. This is particularly important, because time plays an essential role in predicting the clinical outcome and efficacy of treatment in cerebral ischaemia, as demonstrated by the analysis of these recent trials9,10.

Overall, the results were impressive and treatment remained effective across a wide range of ages and initial stroke severity as well as for both patients eligible and ineligible for intravenous tPA11. Moreover, for every 100 patients treated, 38 would have a less disabling sequel, when compared to best medical management alone, with an extra 20 achieving functional independence with endovascular treatment11. Consequently, these compelling results led to updates of the acute stroke guidelines, strongly recommending endovascular therapy after IV tPA in the treatment of acute ischaemic stroke in well-defined settings.

The favourable outcomes attained in these trials clearly mandate the establishment and reorganisation of the management of stroke services. Initial challenges likely to be faced include ensuring a timely transfer of candidates for endovascular therapy to adequate centres. This process includes many factors: increasing public awareness, improving response times of medical services, the initiation of prehospital stroke treatment, effective triage of the patients, and, finally, establishing faster in-hospital action plans12. Another significant challenge is the dispersion of well-equipped centres, capable of performing endovascular stroke interventions.

At present, many countries, including ours (Turkey), lack a sufficient number of centres which can provide a round-the-clock service for endovascular stroke treatment. Furthermore, considering the number of patients requiring endovascular treatment, insufficient procedural volume not supporting a 24/7 available team represents a major logistical challenge, particularly in areas with scattered populations13. These challenges may limit the widespread application of such a promising therapy.

Nonetheless, cardiologists have achieved a similar organisation in the context of acute myocardial infarction (AMI) over recent decades. Moreover, due to the number of procedures they perform, they have become increasingly skilled at catheter-based interventions. This highlights the potential of incorporating present organisations and workforce, in an effort to extend the services of acute stroke management. On the other hand, there are still doubts over this approach, mainly due to the concerns about the lack of a formal training. However, as supporters of this approach, we are aware of the differences in the pathophysiology of AMI and ischaemic stroke, as well as in the course of the disease and the vasculature. Therefore, the involvement of interventional cardiologists, which is of the upmost importance, does not and should not divert training (although it can be shorter), nor replace stroke teams, as this is the best way to manage stroke patients. Indeed, a previous study by our group can serve as an example of this approach: we demonstrated the possibility of attaining similar outcomes in stroke interventions performed by cardiologists working in a stroke team, to those achieved by neurointerventional centres (Figure 1)14. These results were in accordance with the results of studies by other groups15,16.

Figure 1. Case example. A 58-year-old male was admitted to hospital with right-sided weakness which had begun two hours before. Neurologic examination revealed right-sided hemiplegia, aphasia with a National Institutes of Health Stroke Scale (NIHSS) score of 20. Computed tomography with angiography showed total occlusion of the left internal carotid artery and left middle cerebral artery (A & B). This was confirmed on cerebral angiography (C). After treatment with a retrievable stent, good angiographic results were achieved (D). NIHSS score was 4 at the first hour and 2 at discharge.

In conclusion, we are clearly entering into a new era of acute ischaemic stroke treatment, as recent trials and their meta-analysis, including the one by Ferrante et al in this current issue of EuroIntervention, strengthen the role of endovascular treatments. However, there are many questions yet to be answered, including whether we will be able to translate the results of these well-organised and efficient trial settings to the real world. Nonetheless, the revolution of stroke management will require a large multidisciplinary workforce, in which we believe that the involvement of interventional cardiologists would be of benefit.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 12 Number 2
Jun 10, 2016
Volume 12 Number 2
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-22-00002 Apr 1, 2022
Stroke thrombectomy (± thrombolysis), and not thrombolysis alone, should be the gold standard for stroke treatment
Widimský P and Kucera D
free

10.4244/EIJV13I11A200 Dec 20, 2017
When will acute stroke interventions be as widely available as primary PCI?
Widimský P
free

CLINICAL RESEARCH

10.4244/EIJ-D-16-00905 Oct 20, 2017
Endovascular thrombectomy in patients with acute ischaemic stroke and atrial fibrillation: a MR CLEAN subgroup analysis
Heshmatollah A et al
free

SHORT REPORT

10.4244/EIJ-D-17-00684 Mar 20, 2018
Our experience training a neurocardiologist: a case for an emerging specialty
Haldis T et al
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved